EMP3-Suppressed Erythroid Cell Culture for Higher Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for in vitro production of erythroid cells are limited by low yields, failing to meet therapeutic or diagnostic requirements, despite advancements in erythropoiesis and cell culture techniques.
Innovation Solution
Culturing erythroid-producer cells obtained from EMP3-negative individuals or with reduced EMP3 expression, utilizing genetic modification to decrease EMP3 levels, enhances cell proliferation and yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If standard erythroid-producer cells are cultured using conventional methods, then erythroid cells can be produced, but the yield is limited and insufficient for therapeutic use
Solution Approach 1:
The patent changes the biological parameter of EMP3 expression level in erythroid-producer cells. By selecting cells with reduced or absent EMP3 expression (through genetic modification or selection of EMP3-negative donors), the culture system achieves dramatically improved erythroid cell yields, resolving the contradiction between conventional production capability and therapeutic quantity requirements
Solution Approach 2:
The patent extracts or removes the harmful factor EMP3 from the erythroid-producer cells. By knocking out or suppressing EMP3 expression, the culture system eliminates the constraint that limits erythroid cell expansion, thereby achieving the necessary cell quantities for therapeutic applications
2Productivity
If EMP3 expression is reduced in erythroid-producer cells, then cell proliferation and yield increase, but genetic modification complexity increases
Solution Approach 1:
The patent converts the harmful effect of EMP3 (which limits erythroid cell proliferation) into a benefit by removing it. The genetic modification that knocks out EMP3, while adding procedural complexity, ultimately benefits the culture system by enabling sustained high-level proliferation and achieving therapeutic cell yields that were previously unattainable
Data Source
AI summary
A method for producing erythroid cells comprising culturing erythroid-producer cells which are obtainable from an EMP3-negative individual, and/or have reduced expression of EMP3 and/or reduced expression of one or more downstream effectors of the EMP3 pathway.